Is Progyny (PGNY) Priced About Right After New Client Wins?

Progyny has seen its share price move in different directions over recent years, while news of record future client commitments keeps attention on the stock. For anyone watching Progyny today, the key issue is whether the current price around US$27.46 lines up with what its earnings can support.

• Over the past 5 years the share price has fallen 55.2%, which puts the focus squarely on whether the present valuation is still anchored to the business earnings power.
• Management now expects 1.2 million additional covered lives from recent client commitments, which can shape how investors think about future profitability and the earnings base that might justify today's market value.
• There is a second opinion on Progyny worth weighing. See what analysts think Progyny's shares could be worth.

The stock's next move may depend on whether Progyny's current earnings and their trajectory are strong enough to support the price investors are paying today.

If you are weighing whether Progyny's earnings justify its price, it can help to compare that question across a broader set of 33 high quality undervalued stocks.

Where Does Progyny Sit on Earnings?

P/E works well for Progyny because the market focuses heavily on its earnings power and how that supports today’s share price. On this lens, Progyny trades on a P/E of about 26.8x, which is slightly above the broader healthcare sector average of roughly 25.6x and a little below the peer group near 33.3x. That cluster suggests investors are pricing the business with some optimism on its profit stream, but not at the very top end of comparable stocks.

Because the record 2027 selling season commitments have already lifted sentiment, the current P/E sitting close to the modelled fair level suggests the recent enthusiasm is largely reflected in the valuation. The fair multiple, which blends Progyny’s growth profile, margins, size and risk into a tailored benchmark, lands very close to where the shares trade today, so the ratio alone neither clearly cheapens nor clearly stretches the story. To go further, you would weigh how secure those future covered lives look and how much earnings durability you are willing to underwrite at this price. Explore the numbers behind Progyny's P/E valuation.

The Progyny Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Progyny's valuation puzzle leaves off. They spell out what would need to happen to growth, margins and earnings for the stock to be worth meaningfully more or less than it is today. These Narratives live on the platform's Community page as ongoing theses that can be tracked over time, rather than one-off snapshots.

One of the top community narratives on Progyny: 20% undervalued

"Investment in a broader women's and family health platform, including menopause, postpartum support, leave assistance, navigation tools, and AI enabled care management…"

Discover why this Narrative puts Progyny at 20% undervalued.

One more Progyny angle worth checking before you move on

Everything so far has focused on what Progyny looks like today, yet professional coverage also sketches where they think the business could be a few years from now, which gives you one more reference point beside the current multiple. Explore where analysts expect Progyny to be in a few years.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com